Study of Chlorhexidine Gluconate Bladder Washes to Reduce Unplanned Healthcare Visits and Improve Quality of Life in Patients With Neurogenic Bladder Using Suprapubic Catheters

What this Trial Is About

Researchers are evaluating the feasibility and tolerability of 0.05% Chlorhexidine Gluconate CGH bladder instillations in patients with chronic suprapubic catheters who have a history of recurrent urinary tract infections UTIs. The study aims to see if instilling 150mL of CGH during routine catheter exchanges is manageable in an outpatient setting and whether this approach reduces unplanned healthcare visits and improves quality of life. This treatment is being studied because long-term catheter use often leads to frequent infections and antibiotic resistance complications. Participants will receive bladder instillations during their regular suprapubic catheter exchanges in an outpatient setting. The treatment involves three months of bladder instillations with normal saline followed by six months with chlorhexidine gluconate. After these instillation phases, participants will enter a six-month observational phase where catheter exchanges continue without the instillation treatment. During the study, participants will be assessed for tolerability and feasibility of the CGH instillations over nine months. Researchers will also monitor bacteriuria, symptomatic UTIs, catheter biofilm changes, bladder microbiome shifts, unplanned healthcare contacts, and patient quality of life for up to fifteen months. These evaluations include monthly assessments and follow-ups to understand the treatments impact and monitor safety throughout the study period.

Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life